Adrafinil

Adrafinil, known by its development code CRL-40028, is a synthetic wakefulness-promoting agent, or eugeroic. Chemically it is 2-[(diphenylmethyl)sulfinyl]-N-hydroxyacetamide, and it is best understood as a prodrug; it is largely inactive itself and must be metabolized by the liver into its active form, modafinil, along with an inactive byproduct, modafinilic acid ^[1]. Because the body has to perform this conversion, adrafinil works more slowly and requires a larger amount than modafinil to reach an equivalent effect, and it places some additional demand on the liver. It was developed in France by Louis Lafon Laboratories, the company associated with the discovery of modafinil, and was marketed in Europe under the trade name Olmifon for conditions such as excessive sleepiness and reduced alertness in the elderly ^[2].

Pharmacologically, adrafinil belongs to the same class as modafinil and produces vigilance-enhancing and mild stimulant-like effects. In animal studies, adrafinil increased locomotor activity, enhanced learning on a discrimination task, and boosted high-frequency electrical activity in the cortex, indicating genuine cognition-enhancing potential distinct from the stereotyped hyperactivity of classical stimulants ^[2][3]. Its effects are long-lasting and persist over repeated dosing ^[2].

Regulatory and legal status is a defining feature of adrafinil's appeal. While modafinil is a prescription drug in most countries, adrafinil has often occupied an unscheduled position, making it an over-the-counter pathway to modafinil-like effects; however, both adrafinil and modafinil were banned in sport by the World Anti-Doping Agency in 2004 ^[1]. It is typically sold as a powder or in capsules. Analytical toxicology has confirmed that a single dose leaves traces of both adrafinil and its metabolite modafinil detectable in hair, underscoring the prodrug relationship between the two ^[1].

The thing to respect with adrafinil is your liver, since that is where the conversion to modafinil happens. Chronic daily use can bump liver enzymes (GGT and alkaline phosphatase especially), so the smart play is to cycle it and keep use to a few days a week rather than every single day; think of it as an occasional tool, not a daily driver. People with existing liver issues should skip it, and it is worth spacing away from heavy alcohol.

Otherwise the side effect picture mirrors modafinil: occasional headache, some anxiety or overstimulation, dry mouth, and trouble sleeping if you dose too late in the day. It is not a scheduled drug in most places, which is the whole appeal, but it is banned in competitive sport (WADA), and rare but serious skin reactions have been reported with modafinil-class compounds. Skip it in pregnancy, and be careful stacking it with other stimulants or with hormonal birth control, which modafinil can make less effective.

Adrafinil is a prodrug metabolized in the liver to modafinil, so its interaction profile is inferred from modafinil's documented pharmacokinetic interactions rather than from dedicated adrafinil studies. Modafinil induces CYP3A4/5 and can reduce plasma levels of CYP3A4 substrates; the modafinil label specifically warns that this lowers the efficacy of ethinyl estradiol-containing hormonal contraceptives and of cyclosporine. Modafinil also inhibits CYP2C19, which can raise levels of substrates such as phenytoin, diazepam, and propranolol, and warrants monitoring of prothrombin time/INR when combined with warfarin. Because adrafinil carries hepatic burden and elevates liver enzymes, concurrent hepatotoxic agents are a theoretical added concern. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Adrafinil, designated CRL-40028, was discovered in the late 1970s by scientists at the French pharmaceutical company Laboratoire Lafon during a program investigating wakefulness-promoting compounds. It was introduced in France and several other countries under the brand name Olmifon, chiefly to treat attention and alertness problems in older adults. During the study of adrafinil, researchers identified its principal active metabolite, modafinil, which Lafon went on to develop as a distinct and eventually far more prominent medication; adrafinil is therefore best understood as the parent prodrug from which modafinil was derived. Olmifon was discontinued in France in 2011, after which adrafinil largely persisted as an unscheduled, over-the-counter compound in various markets. It is prohibited in competitive sport by the World Anti-Doping Agency.

Adrafinil is popular in nootropic circles as one of the more accessible routes to a clean, sustained sense of wakefulness, valued for delivering modafinil-like alertness without requiring a prescription in many countries. Enthusiasts often describe a smooth, jitter-light energy and improved mental stamina that contrasts with the edginess of classical stimulants. Because its effects arise only after the liver converts it to modafinil, users report a slower and somewhat more variable onset, and the same hepatic conversion is the basis for the most commonly cited caution: chronic use warrants attention to liver health, and periodic monitoring is often recommended. Interest remains steady, tempered by the recognition that human data specific to adrafinil are limited and that most of what is known is inferred from modafinil.